Trump Admin’s Medicaid Drug Price Deals: Status and Challenges
The Trump administration’s high-profile pharmaceutical agreements promised lower drug costs for Medicaid beneficiaries through “most-favored-nation” pricing, yet execution has stalled. In Plain English: The Clinical Takeaway Most-Favored-Nation Pricing: A pricing ... Read More